Predicting EQ-5D-3L utility values from clinical data in a prospective cohort of kidney transplant recipients
- PMID: 40495038
- DOI: 10.1007/s10198-025-01802-6
Predicting EQ-5D-3L utility values from clinical data in a prospective cohort of kidney transplant recipients
Abstract
Objectives: Modelling health-state utility values (HSUVs) from clinical data offers a means to conduct retrospective cost-effectiveness analyses using clinical studies that did not collect direct HSUV measures. Such studies can support the efficient allocation of resources in kidney transplantation (KT). We aim to model KT recipients' EQ-5D-3L HSUVs using routinely collected clinical data.
Methods: From a French observational multicentric prospective cohort, we included 2,787 adult recipients of a first or second single renal graft transplanted between January 2014 and December 2021 who completed 5,679 EQ-5D-3L questionnaires post-KT, from which the HSUVs were calculated. Considering two time periods before and after 1-year post-KT, we estimated a linear mixed effect model (LME), a mixed adjusted limited dependent variable mixture model, and beta and two-part beta mixed models. We compared their predictive performances in terms of precision and calibration.
Results: In each model, recipient age, female sex, higher body mass index, presence of comorbidities and time spent on dialysis prior to KT were associated with lower HSUVs. The predicted HSUVs increased during the first year post-KT before slowly decreasing afterwards. The two-part beta mixed model resulted in the most precise predictions but showed poor calibration. The LME was associated with better calibration than the other models.
Conclusions: Our study illustrates the importance of estimating longitudinal predictive algorithms to consider possible time variations in HSUVs. We provide an online calculator for predicting the HSUVs of KT recipients over time. Future studies in international cohorts are important to support the external validity of our results.
Keywords: EQ-5D; Health-state utility; Kidney transplantation; Longitudinal prediction; Mapping.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval: Data confidentiality was ensured following the recommendations of the French commission for data protection (Commission Nationale Informatique et Liberté, CNIL no. 914184, ClinicalTrials.gov recording NCT02900040). The present study was approved by the DIVAT scientific committee (Données Informatisées et VAlidées en Transplantation; www.divat.fr ). Informed consent was obtained from all individual participants included in the study. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose.
References
-
- Chaudhry, D., Chaudhry, A., Peracha, J., Sharif, A.: Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis. BMJ 376, e068769 (2022). https://doi.org/10.1136/bmj-2021-068769 - DOI - PubMed - PMC
-
- Tonelli, M., Wiebe, N., Knoll, G., Bello, A., Browne, S., Jadhav, D., Klarenbach, S., Gill, J.: Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 11, 2093–2109 (2011). https://doi.org/10.1111/j.1600-6143.2011.03686.x - DOI
-
- Zhang, Y., Gerdtham, U.-G., Rydell, H., Lundgren, T., Jarl, J.: Healthcare costs after kidney transplantation compared to dialysis based on propensity score methods and real world longitudinal register data from Sweden. Sci. Rep. 13, 10730 (2023). https://doi.org/10.1038/s41598-023-37814-6 - DOI - PubMed - PMC
-
- Yang, F., Liao, M., Wang, P., Yang, Z., Liu, Y.: The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations. Appl. Health Econ. Health Policy 19, 163–180 (2021). https://doi.org/10.1007/s40258-020-00614-4 - DOI - PubMed
-
- Winkelmayer, W.C., Weinstein, M.C., Mittleman, M.A., Glynn, R.J., Pliskin, J.S.: Health economic evaluations: the special case of end-stage renal disease treatment. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 22, 417–430 (2002). https://doi.org/10.1177/027298902236927 - DOI
Grants and funding
LinkOut - more resources
Full Text Sources
